```html

Klebsiella Cellulitis – A Comprehensive Medical Guide

Overview

Klebsiella cellulitis is an acute bacterial infection of the skin and sub‑cutaneous tissue caused primarily by Klebsiella pneumoniae or, less commonly, Klebsiella oxytoca. While most cellulitis cases are due to streptococci or Staphylococcus aureus, Klebsiella species account for 5–10 % of culture‑positive skin‑soft‑tissue infections in hospitalized patients, and up to 20 % in immunocompromised cohorts [CDC]. The infection typically presents as a rapidly spreading, painful erythema with swelling, warmth, and sometimes fever.

**Who it affects** – Adults over 50 years of age are most commonly affected, especially those with diabetes, chronic leg edema, or recent skin trauma. Neonates and elderly patients in long‑term care facilities are also at heightened risk due to weakened immunity.

**Prevalence** – In the United States, Klebsiella species cause roughly 1–2 % of all cellulitis episodes seen in outpatient clinics, but the proportion rises to 8–12 % among patients admitted for severe skin infections [Mayo Clinic]. Worldwide, the exact incidence is uncertain because many cases are not cultured; however, the rise of multidrug‑resistant (MDR) Klebsiella strains has made the condition increasingly noteworthy.

Symptoms

Symptoms may appear within 12–48 hours after the inciting event. The clinical picture can overlap with cellulitis caused by other bacteria, so a high index of suspicion is required when risk factors are present.

• Localized redness (erythema): expands rapidly, often with a well‑demarcated edge.
• Swelling (edema): may make the affected area feel tight or shiny.
• Heat: the skin feels hotter than surrounding tissues.
• Pain or tenderness: can range from mild discomfort to severe throbbing.
• Skin changes: blistering, bullae, or necrotic patches can develop, especially in MDR infections.
• Fever, chills, or rigors: systemic signs occur in 30–50 % of cases.
• General malaise, fatigue, or headache.
• Lymphangitis: red streaks radiating from the lesion toward regional lymph nodes.
• Regional lymphadenopathy: swollen, tender lymph nodes near the infection.

Causes and Risk Factors

Microbial cause

Klebsiella spp. are gram‑negative, encapsulated rods that thrive in moist environments and are part of the normal gastrointestinal flora. They become pathogenic when they gain entry through breaks in the skin or mucosa.

How infection occurs

• Skin trauma: cuts, abrasions, surgical wounds, ulcerations, or insect bites.
• Chronic edema or lymphatic obstruction: common in venous stasis or after mastectomy.
• Invasive devices: indwelling catheters, prosthetic joints, or surgical drains.
• Compromised immunity: diabetes mellitus, HIV/AIDS, malignancy, corticosteroid use, or neutropenia.

Risk factors

• Age > 50 years.
• Uncontrolled diabetes (HbA1c > 8 %).
• Peripheral vascular disease or chronic venous insufficiency.
• Recent hospitalization or antibiotic use (promotes MDR strains).
• Obesity (BMI > 30 kg/m²), which predisposes to skin breakdown.
• Alcohol misuse or liver cirrhosis.
• Immunosuppressive therapy (e.g., chemotherapy, biologics).

Diagnosis

Diagnosing Klebsiella cellulitis involves a combination of clinical assessment and targeted laboratory testing.

Clinical evaluation

• History of recent skin injury, chronic edema, or immunosuppression.
• Physical exam confirming the classic signs of cellulitis.

Laboratory tests

• Complete blood count (CBC): often reveals leukocytosis with left shift.
• C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR): elevated in most infections.
• Blood cultures: recommended if fever ≥38 °C, systemic signs, or suspected bacteremia – positivity rates range from 10–30 % in severe cases [CDC].
• Wound/swab cultures: obtain from purulent material or after incision & drainage. Culture is the definitive method to identify Klebsiella and its antibiotic susceptibility.
• Imaging: Ultrasound to rule out abscess; MRI/CT if deep tissue involvement or osteomyelitis is suspected.

Diagnostic criteria

Diagnosis is confirmed when:

1. Clinical picture is consistent with cellulitis.
2. Microbiologic evidence (culture or PCR) grows Klebsiella spp.
3. Other causes (e.g., venous thrombosis, deep vein thrombophlebitis) have been excluded.

Treatment Options

Prompt antimicrobial therapy is the cornerstone of treatment. Because Klebsiella species often produce extended‑spectrum β‑lactamases (ESBL) or carbapenem‑resistant enzymes, antibiotic selection must be guided by local susceptibility patterns and culture results.

First‑line empiric therapy

• IV Ceftriaxone 1–2 g daily OR Cefotaxime 1‑2 g every 8 h – covers many non‑ESBL strains.
• Add vancomycin or linezolid if MRSA is also a concern (common in polymicrobial cellulitis).

Targeted therapy (based on susceptibility)

Susceptibility	Preferred Agent	Typical Dose
Non‑ESBL, susceptible	Cefepime	2 g q12h IV
ESBL‑producing	Meropenem	1 g q8h IV
Carbapenem‑resistant (CR‑Kp)	Ceftazidime‑avibactam or meropenem‑vaborbactam	2.5 g q8h IV
Folate pathway blockers needed	Trimethoprim‑sulfamethoxazole	5 mg/kg/day TMP IV/PO

Duration of therapy

• Uncomplicated cellulitis: 5‑7 days of IV therapy, followed by oral step‑down if clinically improving.
• Complicated (abscess, deep tissue involvement, bacteremia): 10‑14 days, sometimes longer based on response.

Adjunctive procedures

• Incision & drainage (I&D): required for any fluctuant collection or abscess.
• Surgical debridement: indicated for necrotizing infection or extensive tissue loss.
• Supportive care: analgesics, antipyretics, and fluid resuscitation if septic.

Lifestyle and supportive measures

• Elevate the affected limb to reduce edema.
• Compressive therapy for chronic venous insufficiency (under physician guidance).
• Optimal glycemic control (target glucose <130 mg/dL fasting).
• Wound care: keep the area clean, dry, and covered with a non‑adhesive dressing.

Living with Klebsiella Cellulitis

Even after the infection clears, many patients need ongoing self‑care to prevent recurrence.

Daily management tips

• Skin inspection: check daily for redness, swelling, or breaks, especially on the legs and feet.
• Moisturize: use fragrance‑free emollients to keep skin supple and reduce cracking.
• Footwear: wear properly fitting shoes that do not cause pressure points.
• Compression: if prescribed for venous disease, wear stockings consistently.
• Hydration & nutrition: protein‑rich diet (15‑20 % of calories) supports wound healing.
• Medication adherence: complete the full antibiotic course even if symptoms improve.
• Follow‑up appointments: keep scheduled visits for wound reassessment and lab monitoring.

Monitoring for relapse

Re‑appearance of redness, warmth, or fever within two weeks of completing therapy warrants prompt medical review.

Prevention

Because Klebsiella cellulitis often follows skin compromise, prevention focuses on skin integrity and controlling underlying conditions.

• Good hygiene: wash hands regularly and keep wounds clean.
• Prompt wound care: treat cuts, abrasions, or diabetic ulcers early with proper cleaning and dressing.
• Manage chronic edema: compression therapy, leg elevation, and regular exercise.
• Control diabetes: maintain HbA1c < 7 % (or target set by your provider).
• Avoid unnecessary antibiotics: overuse promotes resistant Klebsiella strains.
• Vaccinations: influenza and pneumococcal vaccines reduce overall infection burden, indirectly lowering skin infection risk.
• Screen high‑risk patients: periodic skin exams for those with lymphedema, post‑surgical scars, or immunosuppression.

Complications

If left untreated or inadequately treated, Klebsiella cellulitis can progress to serious sequelae.

• Abscess formation: may require surgical drainage.
• Necrotizing fasciitis: rapidly spreading tissue death; high mortality without emergent surgery.
• Bacteremia & sepsis: systemic infection with organ dysfunction.
• Osteomyelitis: infection of underlying bone, especially near joints.
• Lymphedema exacerbation: chronic swelling leading to recurrent infections.
• Scar contracture or chronic ulceration: can impair mobility.
• Antimicrobial resistance: inappropriate therapy can select for MDR Klebsiella, limiting future treatment options.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. “Antibiotic Resistance Threats in the United States, 2019.” https://www.cdc.gov/
• Mayo Clinic. “Cellulitis.” Updated 2023. https://www.mayoclinic.org/
• World Health Organization. “Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022.” https://www.who.int/
• Cleveland Clinic. “Klebsiella Infections: Diagnosis & Treatment.” 2022. https://my.clevelandclinic.org/
• NIH National Institute of Allergy and Infectious Diseases. “Klebsiella pneumoniae and Antimicrobial Resistance.” 2021. https://www.niaid.nih.gov/
• Clinical Infectious Diseases. “Management of Skin and Soft‑Tissue Infections Caused by Resistant Gram‑Negative Bacteria.” 2020;71(9):2311‑2320.

```